Senior Management Team
Regeneus is led by a senior and experienced team with a strong track record of bringing medical technologies to market.
Karolis Rosickas
Chief Executive Officer
Karolis was appointed CEO of Regeneus on 2 November 2020. Karolis is an experienced executive and healthcare entrepreneur with over 15 years’ business experience in healthcare, technology and finance, including in global businesses. He was most recently CEO and co-founder of OME Health, a nutrition technology business, and co-founded SingCell, a stem cell contract development and manufacturing organisation in Singapore. Karolis has also held senior positions at HSBC, JP Morgan, Danone, Santander Group and KPMG in his career. He holds an MBA from IESE Business School and is CFA qualified.
Pr. Graham Vesey PhD
Chief Scientific Officer and Executive Director
Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director of BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
Dr. Charlotte Morgan PhD
Head of Research and Development
Charlotte is Head of Research and Development and Production. Charlotte joined Regeneus in 2012. She started her career in the UK as a research scientist in the water and microbiology industries. After a move to Australia, she completed a PhD in precise microbiological reference materials, and gained a position as R&D manager at BTF. Since joining Regeneus, the emphasis has been on animal and human cell therapy product development. Our research and development team are responsible for investigational product manufacture for all of our cell therapy product clinical trials and for our human cancer vaccine. They have manufactured investigational products for both animal and human trials.
Sinead Blaber, PhD
Director of Clinical Development and Medical Affairs
Sinéad joined Regeneus as the Director of Clinical Development and Medical Affairs in November 2020. Sinéad completed her PhD in regenerative medicine. She was employed at Regeneus between 2009 and 2017 in both scientific and clinical research roles where she led the Phase I Progenza STEP Trial. Sinéad then joined a Clinical Research Organisation where she was responsible for managing Phase I and II trials of novel Investigational Products including small molecules, antibiotics, vaccines and radioactive pharmaceuticals. Sinéad also managed the Biomedical Translation Bridge Program at UniQuest which aims to fund projects to commercial proof-of-concept. Sinéad is passionate about bridging the gap between science and medicine to deliver innovate treatments that prevent disease, cure patients, or improve quality of life.
Board of Directors
Regeneus leverages its experience Board of Directors to commercialise its novel stem cell therapies.
Barry Sechos
Independent Chairman
Barry has served on the Board since 2012 and has over 20 years experience as a director, business executive and corporate lawyer with particular experience in investment and asset management. Barry is Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the Board of many Sherman Group companies and investee companies.
Pr. Graham Vesey PhD
Chief Scientific Officer and Executive Director
Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director of BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
Leo Lee
Non-Executive Director
Leo has served on the Board since December 2017 and was CEO of Regeneus between 23 January 2019 and 2 November 2020. Leo is a Senior executive with over 20 years of experience in pharmaceutical innovation, commercialisation, regulation and policy. He has worked in North America, Asia and has lived and worked in Japan the last 12 years. Leo was previously held the role of President of Allergan, Japan and Merck, Japan, and following his tenure as CEO of Regeneus, is currently President of Novartis, Japan.